168 related articles for article (PubMed ID: 24252309)
1. Chemokine (C-X-C motif) ligand 1 (CXCL1) protein expression is increased in high-grade prostate cancer.
Miyake M; Lawton A; Goodison S; Urquidi V; Rosser CJ
Pathol Res Pract; 2014 Feb; 210(2):74-8. PubMed ID: 24252309
[TBL] [Abstract][Full Text] [Related]
2. MMP3 and CXCL1 are potent stromal protein markers of dysplasia-carcinoma transition in sporadic colorectal cancer.
Sipos F; Germann TM; Wichmann B; Galamb O; Spisák S; Krenács T; Tulassay Z; Molnár B; Műzes G
Eur J Cancer Prev; 2014 Sep; 23(5):336-43. PubMed ID: 24999605
[TBL] [Abstract][Full Text] [Related]
3. Chemokine (C-X-C) ligand 1 (CXCL1) protein expression is increased in aggressive bladder cancers.
Miyake M; Lawton A; Goodison S; Urquidi V; Gomes-Giacoia E; Zhang G; Ross S; Kim J; Rosser CJ
BMC Cancer; 2013 Jul; 13():322. PubMed ID: 23815949
[TBL] [Abstract][Full Text] [Related]
4. c-met proto-oncogene expression in benign and malignant human prostate tissues.
Pisters LL; Troncoso P; Zhau HE; Li W; von Eschenbach AC; Chung LW
J Urol; 1995 Jul; 154(1):293-8. PubMed ID: 7539865
[TBL] [Abstract][Full Text] [Related]
5. Expression of toll-like receptor-9 is increased in poorly differentiated prostate tumors.
Väisänen MR; Väisänen T; Jukkola-Vuorinen A; Vuopala KS; Desmond R; Selander KS; Vaarala MH
Prostate; 2010 Jun; 70(8):817-24. PubMed ID: 20054821
[TBL] [Abstract][Full Text] [Related]
6. STEAP1 is overexpressed in prostate cancer and prostatic intraepithelial neoplasia lesions, and it is positively associated with Gleason score.
Gomes IM; Arinto P; Lopes C; Santos CR; Maia CJ
Urol Oncol; 2014 Jan; 32(1):53.e23-9. PubMed ID: 24239460
[TBL] [Abstract][Full Text] [Related]
7. CXCL1 promotes tumor growth through VEGF pathway activation and is associated with inferior survival in gastric cancer.
Wei ZW; Xia GK; Wu Y; Chen W; Xiang Z; Schwarz RE; Brekken RA; Awasthi N; He YL; Zhang CH
Cancer Lett; 2015 Apr; 359(2):335-43. PubMed ID: 25641338
[TBL] [Abstract][Full Text] [Related]
8. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology.
Rubin MA; Mucci NR; Figurski J; Fecko A; Pienta KJ; Day ML
Hum Pathol; 2001 Jul; 32(7):690-7. PubMed ID: 11486167
[TBL] [Abstract][Full Text] [Related]
9. Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: change in cellular localization associated with high-grade prostatic intraepithelial neoplasia.
Upadhyay J; Shekarriz B; Nemeth JA; Dong Z; Cummings GD; Fridman R; Sakr W; Grignon DJ; Cher ML
Clin Cancer Res; 1999 Dec; 5(12):4105-10. PubMed ID: 10632347
[TBL] [Abstract][Full Text] [Related]
10. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
Cornford PA; Dodson AR; Parsons KF; Desmond AD; Woolfenden A; Fordham M; Neoptolemos JP; Ke Y; Foster CS
Cancer Res; 2000 Dec; 60(24):7099-105. PubMed ID: 11156417
[TBL] [Abstract][Full Text] [Related]
11. Impact of CXCL1 overexpression on growth and invasion of prostate cancer cell.
Benelli R; Stigliani S; Minghelli S; Carlone S; Ferrari N
Prostate; 2013 Jun; 73(9):941-51. PubMed ID: 23334998
[TBL] [Abstract][Full Text] [Related]
12. Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer.
Ryan CJ; Haqq CM; Simko J; Nonaka DF; Chan JM; Weinberg V; Small EJ; Goldfine ID
Urol Oncol; 2007; 25(2):134-40. PubMed ID: 17349528
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor binding protein-3 (IGFBP-3) in the prostate and in prostate cancer: local production, distribution and secretion pattern indicate a role in stromal-epithelial interaction.
Massoner P; Haag P; Seifarth C; Jurgeit A; Rogatsch H; Doppler W; Bartsch G; Klocker H
Prostate; 2008 Aug; 68(11):1165-78. PubMed ID: 18459102
[TBL] [Abstract][Full Text] [Related]
14. Aberrant expression of cystatin C in prostate cancer is associated with neuroendocrine differentiation.
Jiborn T; Abrahamson M; Gadaleanu V; Lundwall A; Bjartell A
BJU Int; 2006 Jul; 98(1):189-96. PubMed ID: 16831167
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of global DNA hypomethylation in human prostate cancer and prostatic intraepithelial neoplasm tissues by immunohistochemistry.
Yang B; Sun H; Lin W; Hou W; Li H; Zhang L; Li F; Gu Y; Song Y; Li Q; Zhang F
Urol Oncol; 2013 Jul; 31(5):628-34. PubMed ID: 21704537
[TBL] [Abstract][Full Text] [Related]
16. Expression of prostate stem cell antigen (PSCA) in prostate cancer: a tissue microarray study of Iranian patients.
Taeb J; Asgari M; Abolhasani M; Farajollahi MM; Madjd Z
Pathol Res Pract; 2014 Jan; 210(1):18-23. PubMed ID: 24183365
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplasic, and malignant human prostate.
Royuela M; Ricote M; Parsons MS; García-Tuñón I; Paniagua R; de Miguel MP
J Pathol; 2004 Jan; 202(1):41-9. PubMed ID: 14694520
[TBL] [Abstract][Full Text] [Related]
18. Expression of X-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence.
Seligson DB; Hongo F; Huerta-Yepez S; Mizutani Y; Miki T; Yu H; Horvath S; Chia D; Goodglick L; Bonavida B
Clin Cancer Res; 2007 Oct; 13(20):6056-63. PubMed ID: 17947468
[TBL] [Abstract][Full Text] [Related]
19. Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia.
Matos AR; Coutinho-Camillo CM; Thuler LC; Fonseca FP; Soares FA; Silva EA; Gimba ER
Exp Mol Pathol; 2013 Jun; 94(3):438-44. PubMed ID: 23470460
[TBL] [Abstract][Full Text] [Related]
20. Expression of Peroxisome Proliferator Activated Receptor gamma in Prostatic Adenocarcinoma.
Park HK; Kim H; Kim HG; Cho YM; Jung WY; Han HS; Hwang TS; Kwon GY; Lim SD
J Korean Med Sci; 2015 May; 30(5):533-41. PubMed ID: 25931782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
